biopharmaceutical industry 中文意思是什麼
biopharmaceutical industry
解釋
生物制藥業-
Biopharmaceutical industry in china has made rapid progress in the last 10 years. to date, gene therapy for cancers in china has also been studied
近年來，我國生物制藥行業不斷發展，在腫瘤基因治療領域也取得了一定成績。 -
Based on the above - mentioned analysis, we use the theoretical knowledge of project management to elaborate the various possibilities to resolve the problems, and then put forward effective countermeasures, which include analyzing the competition strength of retapase in the biopharmaceutical industry ; evaluating the resources of the fdzj company and its competition strength by using the swot analysis method, collecting the market information by questionnaire survey, interview and document retrieval of domestic and internal literatures. after this, we predict the market requirement and the price of the rctapasc and propose to set up a project management team which can control the r & d, production, sales, finance and affair communicating personnel systematically
本文在深刻剖析上述問題的基礎上，運用項目管理方面的理論知識，充分闡述問題的解決方案，給予了有效的對策。其中包括：項目行業與競爭力分析，運用swot分析法評估公司資源和競爭能力，通過書面調查、訪談及查閱國內外相關文獻等方式收集市場信息，在此基礎上，進行項目的市場需求量預測，價格預測。成立集研發、生產、銷售、財務及公關人才於一身的項目團隊管理項目，並採用強矩陣結構，集合直線制與職能制的優勢，對全體員工實行股份期權激勵，使員工利益與項目形成命運共同體。 -
This research draws conclusions on the choice of the competition strategy, as follows : ( 1 ) the cost leadership strategy has its own scope of application. it is suitable for the middle and small types enterprises which specialize in the production of raw material of chemical medicine and the production of prepared herbal medicine ; ( 2 ) the differentiation strategy has a larger scope of application. it is suitable for the middle and small types pharmaceutical enterprises such as the enterprises in the biopharmaceutical industry, which have their assortment superiority on some extent ; ( 3 ) the focus strategy is suitable for most middle and small types pharmaceutical enterprises
在競爭戰略的選擇上，本文研究得出： （ 1 ）成本領先戰略有一定的適用范圍，即化學藥的原料藥和中藥飲片兩種類型的中小型企業比較適宜採用成本領先戰略； （ 2 ）中小型制藥企業也可以採用差異化戰略，這主要指具有一定品種優勢的中小型制藥企業，特別是在生物制藥領域，此戰略的適用范圍更大； （ 3 ）集中戰略是適合大多數中小型制藥企業的戰略選擇，在化學制藥和中藥方面，集中戰略應該是多數中小型制藥企業的首選，但在生物制藥方沈陽藥科大學碩士畢業論文摘要面，集中戰略並不適合。 -
Starting from 1990s, the plasma protein therapeutics industry, being an important industrial type of the biopharmaceutical field, has stepped into a rapid development period in our country. many producers of plasma - derived products gained noticeable profit
二十世紀九十年代，作為生物製品中的一個重要的產業類別? ?血液製品產業在我國進入了高速發展的時期，其間出現了大量的血液製品生產企業並且都取得了不錯的經濟效益。 -
The research and development mechanism in biopharmaceutical industry must be reformed
生物制藥研發機制必須改革 -
Research on the r amp; amp; d output of chinese biopharmaceutical industry
我國基因工程制藥企業研發產出狀況研究 -
From the history of modern biotechnology, we will find that innovation is the driving force in biopharmaceutical industry
分析國內外醫藥生物技術產業的發展歷程，我們可以看到技術創新在其發展中的重要性。 -
After china has become a member of wto, it faces the very good opportunites to improve this industry. sichuan province has many advantages in biopharmaceutical industry
隨著我國加入wto及世界經濟的一體化，我國在面對國外同行競爭的同時，也面臨著很好的機遇。 -
Biopharmaceutical industry is a typical high - tech industry. as the most important use of the biotechnology, biopharmaceutical industry has a bright future. it ' s development will have a great effect on our society
作為生物技術在制藥產業中的應用，生物制藥產業有著極為光明的發展前景，是公認的朝陽行業。 -
China has set down a series of preferential policies and regulations in order to foster and encourage the development of biopharmaceutical industry and has made great progress in it. biopharmaceutical industry is one of the most dynamic and fastest developing industries in china
我國的生物制藥產業從無到有，從弱到強，經過幾十年的大力發展，雖然與發達國家和地區相比，還有很大的差距，但已初步具備了參與國際競爭的實力和基礎。 -
This thesis analyze the opportunity, chanllenges, advantages, diaadvantages when sichuan develop this area it will face. and on these basis, the thesis give some advice on the development strategy of biopharmaceutical industry of sichuan. at last, the thesis take the sichuan dikang pharmaceutical ltd
四川省有豐富的生物資源，有較多的科研院所和人才，如果能把握住當前生物醫藥發展的大好機遇和形勢，制定切實可行的發展戰略，應該說，四川省的生物制藥產業是大有可為的。 -
By this means we can find out the hotspots and estimate the current researches and development of facilities. compared the situation about gene therapy for cancers in china with that of the whole world, the developmental countermeasures are put forward correspondingly after disadvantages of the area in china being pointed out. methods : current status of biopharmaceutical industry in china and abroad is analysed first as a whole
目的：本課題旨在通過收集國內外腫瘤基因治療專利數據並運用專利分析指標及相應分析方法，了解國內腫瘤基因治療領域的整體現狀及技術發展趨勢，把握其研究熱點及機構研發現狀，並與國外腫瘤基因治療的發展進行對比分析，找出自身發展中存在的不足，提出相應的發展對策。 -
We should use this chance, establish an appropriate strategy and improve the innovation abilities of corporations. the long - term strategic target is to use about 10 years to complete the research for new medicines and then shift to " independent research and development " ; to be in the top level of the world for innovative research and development of new technology and new products in the biopharmaceutical industry ; to make china become the leading center for biotech innovation ; to set up an innovative mechanism with corporations to be the core body and relevant to the international competing situation and self developing disciplines of modern corporations ; to bring up a batch of entities with competing capacities in the market and independent exploitation abilities ; to be a leading country with great power in biotech industry. joint exploitation, improvement and innovation, dividing market into even smaller fractions, and cost minimization are the main conditions for realizing the strategic target
本論文從分析國內外生物技術企業的發展環境和發展特點入手，闡述我國生物技術企業加強科技創新的重要性和可行性，結合國情現狀研究我國生物技術企業的科技創新戰略，提出我國醫藥生物技術產業的長期戰略目標應該是「用十年左右的時間，完成新藥研究向"自主研發"的轉移，在新技術、新產品的創新性研發方面躋身世界醫藥生物技術產業的領先行列，將中國建設成為世界一流的生物技術創新中心，建立健全以企業為核心的適應國際醫藥競爭形勢和現代企業自身發展規律的技術創新運行機制體系，培養一批具有市場競爭力和自主開發能力的骨幹創新實體，成為世界生物技術產業強國" 。
分享友人